公开(公告)号：WO2008070663A2

公开(公告)日：2008-06-12

申请号：PCT/US2007086382

申请日：2007-12-04

Applicant: ABBOTT LAB ,  ANDERSON MARK GERALD ,  KROEGER PAUL E ,  ROSENBERG SAUL HOWARD ,  TAHIR STEPHEN KENNETH ,  TSE CHRISTIN ,  WASS JOHN A

Inventor： ANDERSON MARK GERALD ,  KROEGER PAUL E ,  ROSENBERG SAUL HOWARD ,  TAHIR STEPHEN KENNETH ,  TSE CHRISTIN ,  WASS JOHN A

IPC: C12Q1/68

CPC classification number: C12Q1/6886 ,  C12Q2600/106 ,  Y02A90/26

Abstract: Methods for identifying cancer patients eligible to receive Bcl-2 family inhibitor therapy and for monitoring patient response to Bcl-2 family inhibitor therapy comprise assessment of the expression levels of the biomarker combinations set out in TABLES 1, 2, 3, 4, 5 or 6 in a patient tissue sample. The methods of the invention allow more effective identification of patients to receive Bcl-2 family inhibitor therapy and of determination of patient response to the therapy.

Abstract translation: 鉴定符合接受Bcl-2家族抑制剂治疗和监测患者对Bcl-2家族抑制剂治疗的反应的癌症患者的方法包括评估表1,2,3,4,5或5所示生物标志物组合的表达水平 6在患者组织样品中。 本发明的方法允许更有效地鉴定患者接受Bcl-2家族抑制剂治疗和确定患者对治疗的反应。

公开(公告)号：EP2106451A4

公开(公告)日：2010-12-15

申请号：EP07865171

申请日：2007-12-04

Applicant: ABBOTT LAB

Inventor： ANDERSON MARK GERALD ,  KROEGER PAUL E ,  ROSENBERG SAUL HOWARD ,  TAHIR STEPHEN KENNETH ,  TSE CHRISTIN ,  WASS JOHN A

IPC: C12Q1/68

CPC classification number: C12Q1/6886 ,  C12Q2600/106 ,  Y02A90/26

Abstract: Methods for identifying cancer patients eligible to receive Bcl-2 family inhibitor therapy and for monitoring patient response to Bcl-2 family inhibitor therapy comprise assessment of the expression levels of the biomarker combinations set out in TABLES 1, 2, 3, 4, 5 or 6 in a patient tissue sample. The methods of the invention allow more effective identification of patients to receive Bcl-2 family inhibitor therapy and of determination of patient response to the therapy.

公开(公告)号：BRPI0719563A2

公开(公告)日：2013-12-10

申请号：BRPI0719563

申请日：2007-12-04

Applicant: ABBOTT LAB

Inventor： ANDERSON MARK GERALD ,  KROEGER PAUL E ,  ROSENBERG SAUL HOWARD ,  TAHIR STEPHEN KENNETH ,  TSE CHRISTIN ,  WASS JOHN A

IPC: C12Q1/68

Abstract: Methods for identifying cancer patients eligible to receive Bcl-2 family inhibitor therapy and for monitoring patient response to Bcl-2 family inhibitor therapy comprise assessment of the expression levels of the biomarker combinations set out in TABLES 1, 2, 3, 4, 5 or 6 in a patient tissue sample. The methods of the invention allow more effective identification of patients to receive Bcl-2 family inhibitor therapy and of determination of patient response to the therapy.

公开(公告)号：AU2007329458A1

公开(公告)日：2008-06-12

申请号：AU2007329458

申请日：2007-12-04

Applicant: ABBOTT LAB

Inventor： ROSENBERG SAUL HOWARD ,  KROEGER PAUL E ,  WASS JOHN A ,  TSE CHRISTIN ,  ANDERSON MARK GERALD ,  TAHIR STEPHEN KENNETH

IPC: C12Q1/68

Abstract: Methods for identifying cancer patients eligible to receive Bcl-2 family inhibitor therapy and for monitoring patient response to Bcl-2 family inhibitor therapy comprise assessment of the expression levels of the biomarker combinations set out in TABLES 1, 2, 3, 4, 5 or 6 in a patient tissue sample. The methods of the invention allow more effective identification of patients to receive Bcl-2 family inhibitor therapy and of determination of patient response to the therapy.

公开(公告)号：MX2009005941A

公开(公告)日：2009-07-24

申请号：MX2009005941

申请日：2007-12-04

Applicant: ABBOTT LAB

Inventor： ANDERSON MARK GERALD ,  KROEGER PAUL E ,  ROSENBERG SAUL HOWARD ,  TAHIR STEPHEN KENNETH ,  TSE CHRISTIN ,  WASS JOHN A

IPC: C12Q1/68

Abstract: Se describen métodos para identificar pacientes con cáncer elegibles para recibir la terapia del inhibidor de la familia Bcl-2 y para supervisar la respuesta del paciente a la terapia del inhibidor de la familia Bcl-2, que comprende la evaluación de los niveles de expresión del conjunto de combinaciones del marcador biológico en las tablas 1, 2, 3, 4, 5, ó 6 en una muestra de tejido del paciente. Los métodos de la invención permiten más eficiencia en la identificación de pacientes para recibir la terapia del inhibidor de la familia Bcl-2 y de la determinación de la respuesta del paciente a la terapia.

公开(公告)号：CA2671399A1

公开(公告)日：2008-06-12

申请号：CA2671399

申请日：2007-12-04

Applicant: ABBOTT LAB

Inventor： KROEGER PAUL E ,  TAHIR STEPHEN KENNETH ,  ROSENBERG SAUL HOWARD ,  TSE CHRISTIN ,  WASS JOHN A ,  ANDERSON MARK GERALD

IPC: C12Q1/68 ,  C40B30/04 ,  G06F19/00

Abstract: Methods for identifying cancer patients eligible to receive Bcl-2 family inhibitor therapy and for monitoring patient response to Bcl-2 family inhibi tor therapy comprise assessment of the expression levels of the biomarker co mbinations set out in TABLES 1, 2, 3, 4, 5 or 6 in a patient tissue sample. The methods of the invention allow more effective identification of patients to receive Bcl-2 family inhibitor therapy and of determination of patient r esponse to the therapy.